Latest News | Glenmark Pharmaceuticals Gets USFDA Nod for Fingolimod Capsules

New Delhi, Jun 19 (PTI) Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.

The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.

Also Read | Facebook Removes US President Donald Trump's Ad for Violating Its Policies.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.

According to IQVIA sales data for the 12-month period ending April 2020, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately USD 2.1 billion, the company said.

Also Read | 2020 Mercedes-Benz GLS Flagship SUV Launched in India at Rs 99.90 Lakh; Prices, Features & Specifications.

Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 411.20 a piece on BSE in morning trade, up 1.44 per cent from their previous close.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)